评估重组促红细胞生成素在肾源性系统性纤维化中的作用。 - Suppr

Suppr

超能文献

Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.

作者信息

Goveia Michelle, Chan Benjamin P, Patel Priti R

出版信息

J Am Acad Dermatol. 2007 Oct;57(4):725-7. doi: 10.1016/j.jaad.2007.07.010. Epub 2007 Aug 8.

DOI:10.1016/j.jaad.2007.07.010

PMID:17689832

Abstract

摘要

相似文献

Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.

J Am Acad Dermatol. 2007 Oct;57(4):725-7. doi: 10.1016/j.jaad.2007.07.010. Epub 2007 Aug 8.

Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders.

Arthritis Rheum. 2007 Oct;56(10):3173-5. doi: 10.1002/art.22926.

Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.

Intern Med J. 2007 Jul;37(7):508-9; author reply 509. doi: 10.1111/j.1445-5994.2007.01413.x.

Nephrogenic systemic fibrosis: is any contrast safe in renal failure?

Intern Med J. 2007 Jul;37(7):429-31. doi: 10.1111/j.1445-5994.2007.01401.x.

Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease.

Am J Med. 2007 Jul;120(7):561-2. doi: 10.1016/j.amjmed.2007.01.032.

Epoetin and nephrogenic systemic fibrosis.

J Am Acad Dermatol. 2008 Jan;58(1):174-5. doi: 10.1016/j.jaad.2007.10.012.

Nephrogenic systemic fibrosis: a clinicopathologic study of six cases.

J Am Acad Dermatol. 2007 Jul;57(1):105-11. doi: 10.1016/j.jaad.2007.02.021. Epub 2007 Apr 6.

Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.

Nephrol Dial Transplant. 2007 Nov;22(11):3179-85. doi: 10.1093/ndt/gfm584. Epub 2007 Sep 21.

Nephrogenic systemic fibrosis: a dermatologist's perspective.

J Am Coll Radiol. 2008 Jan;5(1):40-4. doi: 10.1016/j.jacr.2007.08.017.

Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease.

Am J Med. 2008 Jan;121(1):e11; author reply e13. doi: 10.1016/j.amjmed.2007.07.030.

引用本文的文献

10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.

Invest Radiol. 2018 Sep;53(9):541-550. doi: 10.1097/RLI.0000000000000462.

Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.

Invest Radiol. 2017 Jan;52(1):55-60. doi: 10.1097/RLI.0000000000000307.

Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure.

NDT Plus. 2008 Jun;1(3):193-4. doi: 10.1093/ndtplus/sfn030.

Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.

Invest Radiol. 2015 Jun;50(6):416-22. doi: 10.1097/RLI.0000000000000145.

Gadolinium and nephrogenic systemic fibrosis: an update.

Pediatr Nephrol. 2014 Oct;29(10):1927-37. doi: 10.1007/s00467-013-2636-z. Epub 2013 Oct 22.

Nephrogenic systemic fibrosis: current concepts.

Indian J Dermatol. 2011 Jan;56(1):59-64. doi: 10.4103/0019-5154.77555.

Nephrogenic systemic fibrosis in liver disease: a systematic review.

J Magn Reson Imaging. 2009 Dec;30(6):1313-22. doi: 10.1002/jmri.21983.

Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.

J Urol. 2008 Sep;180(3):830-5; discussion 835. doi: 10.1016/j.juro.2008.05.005. Epub 2008 Jul 17.

Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.

Pediatr Nephrol. 2008 Dec;23(12):2121-9. doi: 10.1007/s00467-008-0862-6. Epub 2008 Jun 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.

作者信息

Goveia Michelle, Chan Benjamin P, Patel Priti R

出版信息

J Am Acad Dermatol. 2007 Oct;57(4):725-7. doi: 10.1016/j.jaad.2007.07.010. Epub 2007 Aug 8.

DOI:10.1016/j.jaad.2007.07.010

PMID:17689832

Abstract

摘要

相似文献

Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis.

J Am Acad Dermatol. 2007 Oct;57(4):725-7. doi: 10.1016/j.jaad.2007.07.010. Epub 2007 Aug 8.

Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders.

Arthritis Rheum. 2007 Oct;56(10):3173-5. doi: 10.1002/art.22926.

Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.

Intern Med J. 2007 Jul;37(7):508-9; author reply 509. doi: 10.1111/j.1445-5994.2007.01413.x.

Nephrogenic systemic fibrosis: is any contrast safe in renal failure?

Intern Med J. 2007 Jul;37(7):429-31. doi: 10.1111/j.1445-5994.2007.01401.x.

Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease.

Am J Med. 2007 Jul;120(7):561-2. doi: 10.1016/j.amjmed.2007.01.032.

Epoetin and nephrogenic systemic fibrosis.

J Am Acad Dermatol. 2008 Jan;58(1):174-5. doi: 10.1016/j.jaad.2007.10.012.

Nephrogenic systemic fibrosis: a clinicopathologic study of six cases.

J Am Acad Dermatol. 2007 Jul;57(1):105-11. doi: 10.1016/j.jaad.2007.02.021. Epub 2007 Apr 6.

Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.

Nephrol Dial Transplant. 2007 Nov;22(11):3179-85. doi: 10.1093/ndt/gfm584. Epub 2007 Sep 21.

Nephrogenic systemic fibrosis: a dermatologist's perspective.

J Am Coll Radiol. 2008 Jan;5(1):40-4. doi: 10.1016/j.jacr.2007.08.017.

Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease.

Am J Med. 2008 Jan;121(1):e11; author reply e13. doi: 10.1016/j.amjmed.2007.07.030.

引用本文的文献

10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.

Invest Radiol. 2018 Sep;53(9):541-550. doi: 10.1097/RLI.0000000000000462.

Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.

Invest Radiol. 2017 Jan;52(1):55-60. doi: 10.1097/RLI.0000000000000307.

Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure.

NDT Plus. 2008 Jun;1(3):193-4. doi: 10.1093/ndtplus/sfn030.

Invest Radiol. 2015 Jun;50(6):416-22. doi: 10.1097/RLI.0000000000000145.

Gadolinium and nephrogenic systemic fibrosis: an update.

Pediatr Nephrol. 2014 Oct;29(10):1927-37. doi: 10.1007/s00467-013-2636-z. Epub 2013 Oct 22.

Nephrogenic systemic fibrosis: current concepts.

Indian J Dermatol. 2011 Jan;56(1):59-64. doi: 10.4103/0019-5154.77555.

Nephrogenic systemic fibrosis in liver disease: a systematic review.

J Magn Reson Imaging. 2009 Dec;30(6):1313-22. doi: 10.1002/jmri.21983.

Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.

J Urol. 2008 Sep;180(3):830-5; discussion 835. doi: 10.1016/j.juro.2008.05.005. Epub 2008 Jul 17.

Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.

Pediatr Nephrol. 2008 Dec;23(12):2121-9. doi: 10.1007/s00467-008-0862-6. Epub 2008 Jun 10.